<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00426842</url>
  </required_header>
  <id_info>
    <org_study_id>00893</org_study_id>
    <secondary_id>VA Project #5481-06-051</secondary_id>
    <nct_id>NCT00426842</nct_id>
  </id_info>
  <brief_title>A Dose Response Trial Using 5 and 10 Mg of Midodrine Hydrochloride</brief_title>
  <official_title>A Dose Response Trial Using 5 and 10 mg. of Midodrine Hydrochloride to Treat Orthostatic Hypotension in Persons With SCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>James J. Peters Veterans Affairs Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>James J. Peters Veterans Affairs Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With upright postures, there is an immediate redistribution of blood to the dependent
      circulation; venous return and central venous filling pressure are reduced, resulting in
      diminution of cardiac output and blood pressure. These hemodynamic alterations stimulate the
      baroreceptor reflex, which is mediated via the central nervous system to increase peripheral
      sympathetic vasomotor tone, restoring blood pressure and cardiac output within
      seconds-to-minutes of the assumption of the upright position. Following SCI, individuals
      often experience the inability to adjust to postural changes due to disruption of central
      command of the baroreceptor reflex and reduction in efferent sympathetic neural pathways;
      consequently, orthostatic hypotension (OH) and symptoms of cerebral hypo-perfusion may ensue.
      OH is a well-documented phenomenon, which is characterized by a fall in systolic blood
      pressure of &gt;20 mmHg or diastolic BP of &gt; 10 mmHg within 3 minutes of assumption of an
      upright posture. As a consequence of OH, many individuals experience symptoms of cerebral
      hypo-perfusion which include lightheadedness, dizziness, blurry vision, fatigue, nausea,
      ringing in the ears, cognitive impairment and heart palpitations. Although several
      investigators have reported increased prevalence of OH during the acute phase of spinal cord
      injury (SCI), individuals with chronic injury also experience significant falls in blood
      pressure with seated upright postures. This investigation will examine the effects of an
      alpha-agonist, midodrine hydrochloride, during head-up tilt on systemic blood pressure,
      cerebral blood flow and cerebral oxygenation compared to placebo administration in persons
      with chronic SCI who demonstrate significant orthostatic hypotension during a 24-hour
      observation study. This is the first study to determine the dose response and efficacy of
      midodrine to improve orthostatic blood pressure and cerebral blood flow and oxygenation in
      the SCI population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In individuals with SCI, blood pressure regulation is altered compared to the non-SCI
      population and relates to the degree of sympathetic vascular denervation. The inadequate
      release of norepinephrine with postural change is a primary component of OH and several
      reports have documented significantly reduced plasma norepinephrine levels in individuals
      with tetraplegia. Ephedrine sulfate and midodrine hydrochloride, both 1 receptor agonists,
      are recommended for the treatment of postural hypotension in this population. Although there
      are case reports documenting improved blood pressure regulation in persons with SCI treated
      with an 1 receptor agonist, this pharmacological treatment for OH has not been adequately
      studied in this population. A dose response trial will be used to determine the efficacy of
      midodrine hydrochloride (5 and 10 mg) compared to no drug at improving systemic blood
      pressure, cerebral blood flow and oxygenation and at reducing symptomatic hypotension during
      tilt-table testing in 16 individuals with SCI who manifest significant orthostatic
      hypotension (total time [minutes] spent with hypotension [ 20% fall in mean arterial pressure
      from supine laboratory observation] over a 24-hour observation.

      Subjects will receive, in an increasing dose manner and on separate days: no drug, 5 and 10
      mg of oral midodrine hydrochloride. Oral ingestion of the pill (placebo or midodrine) will be
      at 30 minutes during the 60 minute supine rest period prior to the head-up tilt maneuver.

      A progressive head-up tilt will be utilized in which the table will be adjusted to 15 , 25 ,
      35 for 5 minutes at each angle and then will be maintained at 45 for 45 minutes or until the
      subjects experiences symptoms of compromised cerebral blood flow, which include, but are not
      limited to, light headedness, blurry vision, dizziness and nausea. Throughout each test day,
      measurements of heart rate, blood pressure, middle cerebral blood flow velocity, and cerebral
      oxygenation will be obtained. In addition, blood draws will be completed to capture humoral
      factors responsible for blood pressure regulation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>The difference between the average supine systolic blood pressure and the average systolic blood pressure at 45 degree head-up tilt position.</time_frame>
    <description>brachial artery systolic blood pressure (mmHg)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Orthostatic Hypotension</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine Hydrochloride</intervention_name>
    <description>Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  This study will be performed on subjects 18 to 65 years old, with chronic SCI (&gt; 1
             year), who are neurologically stable and have demonstrated significant hypotension
             (total time [proportion 50%] spent with hypotension [systolic BP below 110 mmHg for
             males and 100 mmHg for females] during a 24-hour observation.

        Exclusion Criteria:

          -  hypertension

          -  diabetes

          -  vascular disease

          -  cardiac disease

          -  cardiovascular medication

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jill Wecht, EdD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Bronx</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Bauman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Bronx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wecht JM, Rosado-Rivera D, Handrakis JP, Radulovic M, Bauman WA. Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. Arch Phys Med Rehabil. 2010 Sep;91(9):1429-35. doi: 10.1016/j.apmr.2010.06.017.</citation>
    <PMID>20801263</PMID>
  </results_reference>
  <results_reference>
    <citation>Wecht JM, Radulovic M, Rosado-Rivera D, Zhang RL, LaFountaine MF, Bauman WA. Orthostatic effects of midodrine versus L-NAME on cerebral blood flow and the renin-angiotensin-aldosterone system in tetraplegia. Arch Phys Med Rehabil. 2011 Nov;92(11):1789-95. doi: 10.1016/j.apmr.2011.03.022. Epub 2011 Jul 16.</citation>
    <PMID>21762873</PMID>
  </results_reference>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2007</study_first_submitted>
  <study_first_submitted_qc>January 24, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2007</study_first_posted>
  <results_first_submitted>September 17, 2013</results_first_submitted>
  <results_first_submitted_qc>May 8, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2015</results_first_posted>
  <last_update_submitted>August 29, 2016</last_update_submitted>
  <last_update_submitted_qc>August 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>James J. Peters Veterans Affairs Medical Center</investigator_affiliation>
    <investigator_full_name>Jill M. Wecht, Ed.D.</investigator_full_name>
    <investigator_title>Research Health Scientist</investigator_title>
  </responsible_party>
  <keyword>Blood pressure</keyword>
  <keyword>Orthostatic hypotension</keyword>
  <keyword>Spinal Cord Injury</keyword>
  <keyword>Sympathetic vascular control</keyword>
  <keyword>Midodrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Hypotension</mesh_term>
    <mesh_term>Hypotension, Orthostatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2008-2010</recruitment_details>
      <pre_assignment_details>no subject was excluded from study participate prior to group assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>All participants underwent a head-up tilt maneuver following no-drug, midodrine 5 mg and midodrine 10 mg, in that order, on seperate study visits. Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm 1</title>
          <description>Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Systolic Blood Pressure</title>
        <description>brachial artery systolic blood pressure (mmHg)</description>
        <time_frame>The difference between the average supine systolic blood pressure and the average systolic blood pressure at 45 degree head-up tilt position.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>No-drug</title>
          </group>
          <group group_id="O2">
            <title>Midodrine 5 mg</title>
          </group>
          <group group_id="O3">
            <title>Midodrine 10 mg</title>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>brachial artery systolic blood pressure (mmHg)</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" spread="5"/>
                    <measurement group_id="O2" value="97" spread="5"/>
                    <measurement group_id="O3" value="102" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head-up Tilt Blood Pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" spread="15"/>
                    <measurement group_id="O2" value="96" spread="19"/>
                    <measurement group_id="O3" value="109" spread="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Blood pressure response during HUT following administration of Midodrine Hydrochloride compared with no drug.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A matching placebo tablet was not used and the order of testing was not randomized. The total number of subjects recruited was relatively small and extrapolation to a broader group of individuals with chronic SCI may not be appropriate.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jill M. Wecht</name_or_title>
      <organization>James J Peters VAMC</organization>
      <phone>718-584-9000 ext 3122</phone>
      <email>jm.wecht@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

